ASP Isotopes (NASDAQ:ASPI) Director Sells $624,000.00 in Stock

Key Points

• Director Insider Sale: ASP Isotopes Director Michael Gorley sold 64,000 shares for $624,000, reducing his stake by 44.03% to 81,360 shares.
• Earnings Miss: The company reported a loss of $1.03 per share for the last quarter, significantly below analysts' expectations of a loss of $0.11 per share.
• Institutional Investment Growth: Several institutional investors increased their holdings in ASP Isotopes during the last quarter, indicating growing interest in the stock.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director Michael Gorley sold 64,000 shares of the business's stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $9.75, for a total transaction of $624,000.00. Following the completion of the transaction, the director owned 81,360 shares in the company, valued at approximately $793,260. This trade represents a 44.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ASP Isotopes Price Performance

Shares of ASPI stock traded down $0.10 during trading hours on Thursday, reaching $8.99. 6,506,687 shares of the company were exchanged, compared to its average volume of 5,188,385. ASP Isotopes Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $11.86. The stock's fifty day moving average is $9.55 and its two-hundred day moving average is $7.69. The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. On average, equities analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On ASP Isotopes

Several large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its holdings in ASP Isotopes by 41.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock worth $40,000 after purchasing an additional 1,600 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in ASP Isotopes by 9.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company's stock worth $153,000 after purchasing an additional 1,878 shares during the last quarter. Bank of Montreal Can boosted its holdings in ASP Isotopes by 8.0% during the second quarter. Bank of Montreal Can now owns 27,000 shares of the company's stock worth $199,000 after purchasing an additional 2,000 shares during the last quarter. Rathbones Group PLC boosted its holdings in ASP Isotopes by 1.1% during the second quarter. Rathbones Group PLC now owns 208,149 shares of the company's stock worth $1,532,000 after purchasing an additional 2,220 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock worth $41,000 after purchasing an additional 2,548 shares during the last quarter. Institutional investors own 16.80% of the company's stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reissued a "buy" rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Wednesday, September 17th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, ASP Isotopes has a consensus rating of "Buy" and an average price target of $7.75.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.